Fractyl Health to Report Third Quarter 2026 Financial Results on November 12, 2026
Fractyl Health, Inc. announced it will release its financial results for the third quarter of 2026 and provide business updates on November 12, 2026.
Stocks · News reference
U.S. stocks mixed: Dow +0.48%, Nasdaq -0.65%, S&P -0.05%. Energy rose, tech fell, and M&T Bank beat Q3 estimates; oil eased, gold gained.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Fractyl Health, Inc. announced it will release its financial results for the third quarter of 2026 and provide business updates on November 12, 2026.
Fractyl Health, a clinical-stage metabolic therapeutics company, announced it will report Q3 2026 financial results on November 12, 2026. The company is advancing its lead product Revita, an endoscopic procedural therapy for post-GLP-1 weight maintenance, toward FDA submission. Fractyl has strengthened its patent portfolio and released market research showing substantial patient interest in one-time procedural approaches, with approximately one million U.S. patients monthly discontinuing GLP-1 medications.
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
M&T Bank has updated its credit card rewards program to offer increased point earnings on grocery and gas station purchases.
Fractyl Health reported the strengthening of its patent portfolio for its Revita DMR system as it progresses toward FDA submission.
MDxHealth SA announced it will release its financial results for the third quarter ended September 30, 2026, after market close on November 12, 2026.